Staying Vigilant for Immunocompromised Patients
Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir.
Akinosoglou K, Schinas G, Gogos C. Viruses. 2022;14(11):2540.
Coronavirus disease-2019 in the immunocompromised host.
Bertini CD Jr, Khawaja F, Sheshadri A. Clin Chest Med. 2023;44(2):395-406.
Racial and ethnic disparities in outpatient treatment of COVID-19—United States, January–July 2022.
Boehmer TK, Koumans EH, Skillen EL, et al. MMWR Morb Mortal Wkly Rep. 2022;71(43):1359-1365.
Safety and immunogenicity of XBB.1.5-containing mRNA vaccines.
Chalkias S, McGhee N, Whatley JL, et al. medRxiv. 2023:2023.08.22.23293434. [Preprint].
Cancer, more than a "COVID-19 co-morbidity."
Jani CT, Schooley RT, McKay RR, et al. Front Oncol. 2023;13:1107384.
Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study.
Kang SW, Kim JW, Kim JY, et al. J Infect. 2023;86(4):412-414.
Immune response to COVID-19 and mRNA vaccination in immunocompromised individuals: a narrative review.
Napuri NI, Curcio D, Swerdlow DL, et al. Infect Dis Ther. 2022;11(4):1391-1414.
Managing patients who are immunocompromised during the COVID-19 pandemic.
Pullen RL Jr. Nursing. 2022;52(12):27-32.
Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients.
Schmidt T, Klemis V, Schub D, et al. Am J Transplant. 2021;21(12):3990-4002.
Clinical Practice Guidelines
COVID-19 Treatment Guidelines.
National Institutes of Health (NIH).
Clinician Resources
Use of COVID-19 vaccines in the U.S.
Centers for Disease Control and Prevention (CDC).
Fact sheet for healthcare providers: emergency use authorization for Lagevrio™ (molnupiravir).
US Food and Drug Administration (FDA).
Fact sheet for healthcare providers: emergency use authorization for PaxlovidTM.
FDA.
Highlights of prescribing information: Veklury® (remdesivir).
FDA.
COVID-19 drug interactions.
University of Liverpool.
Staying Vigilant for Immunocompromised Patients
Insights from a COVID-19 Expert Working Group
| Faculty: | Eric S. Daar, MD; Roger J. Bedimo, MD; Brinda Emu, MD |
| Release: | 10/13/2023 |
| Expiration: | 11/10/2023 |
Staying Vigilant for Immunocompromised Patients
Insights from a COVID-19 Expert Working Group
| Faculty: | Eric S. Daar, MD; Roger J. Bedimo, MD; Brinda Emu, MD |
| Release: | 11/15/2023 |
| Expiration: | 11/15/2024 |
